13 Best Multibagger Stocks to Invest in Now

Page 11 of 13

3. Autolus Therapeutics plc (NASDAQ:AUTL)

Upside Potential:           697.60%

Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company specializing in the development of T-cell therapies for the treatment of cancer and autoimmune diseases. Established in 2014, Autolus is advancing innovative approaches in the field of chimeric antigen receptor (CAR) T-cell therapy, aiming to transform patient outcomes with cutting-edge science and technology.

Autolus has strategically positioned itself to meet global demand through its dedicated commercial manufacturing facility, known as “The Nucleus,” located in the UK. This facility not only supports clinical and commercial production requirements but also ensures scalability and flexibility, enabling the company to cater to expanding markets. Autolus retains worldwide commercial rights to its products and maintains a focused marketing strategy targeting key regions such as the United States, the United Kingdom, and Europe. This strategic approach highlights the company’s commitment to delivering transformative therapies across diverse geographic markets while ensuring the highest standards of quality in production.

Further analysis of the company’s business model and financial performance reflect its significant progress in advancing CAR T-cell therapy. In the first quarter of 2025, Autolus posted revenue of $9 million, demonstrating steady growth. For the full year of 2024, the company reported $45.8 million in revenue, driven by its pioneering efforts in cancer treatment development. With $210 million in cash reserves, Autolus is well-positioned to support the commercialization plans for its therapies and sustain future research and development endeavors. This financial stability has contributed to a positive outlook among analysts, who project the company’s share price to reach $9.97 within the next twelve months, offering an upside potential of 697.60%. Through its relentless pursuit of innovation and financial health, Autolus Therapeutics plc remains at the forefront of oncology treatment, pushing boundaries and redefining possibilities in CAR T-cell therapy.

Page 11 of 13